December 22, 2022 7:18am

Some cell and gene therapy sector equities might be flashing buy signals, but in a shaky and sinking market

Pre-open Indication: downside equity NEGATIVITY!

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

The Christmas holiday is starting for me with a limited review for the week, the 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.15% or (-52 points), S&P futures are DOWN -0.12% or (-4 point) and NASDAQ futures are DOWN -0.12% or (-13 points) early in the pre-open – so far,

Stock futures are slipping in early trading on Thursday,

European markets are marginally higher,

Asia-Pacific markets traded higher



We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Last night, indexes rose for a second day (Wednesday) after earnings reports from two bellwethers (Nike and FedEx) raised hopes that corporate earnings may be better than feared even with a potential recession.

·         The Dow closed UP +526.74 points (+1.60%), the S&P closed UP +56.81 points (+1.49%) while the Nasdaq closed UP +162.26 points (+1.54%)

Economic Data Docket: unemployment insurance claims for the week of Dec. 17

Wednesday’s (9/21) … RegMed Investors’ (RMi) closing bell: “two-day confidence bounce. How long will it last (?) until electronic trading wants to end the year with dramatic returns. I would also be more than worried by … about the upcoming quarter earnings season.”


Ebb and flow:

Q4 – December – 9 negative and 6 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

I am passing on any Positive or Negative indications – “Let ‘em ride”!

Although I foretell … some downside equity NEGATIVITY!


The BOTTOM LINE: I try to keep it simple and short!

Many cell and gene therapy equities experience a boost after being oversold; however, whether they'll hold and rebound is largely dependent on the overall market and IF support levels stay or even fall into place.

The past week’s cell and gene therapy sector roll-call …

·         Wednesday closed positive with 22 incliners, 12 decliners and 1 flat,

·         Tuesday closed positive with 25 incliners, 7 decliners and 3 flats.

·         Monday closed negative with 4 incliner, 30 decliners and 1 flat

·         Friday closed negative with 16 incliner, 19 decliners and 0 flats

·         The previous Thursday closed negative with 6 incliner, 28 decliners and 1 flat

Sector equities “could extend pain” as markets fluidity is shifting on Thursday.

Be prepared … just 7 trading days remain in 2022.

Still, until December 31, investors may want to be cautious about making new buys.

I’d be calculating selling for tax purposes amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.